MoonLake Immunotherapeutics
Company Stats
- Market Cap
- $995.7M
- as of Sep 30, 2026
- Shares Outstanding
- 85.1M
- Free Float
- 71.9%
Income Statement
- Operating Income
- -$244.8M
- Net Income
- -$227.3M
- EBITDA
- -$242.2M
Cash Flow
- Free Cash Flow
- -$196.0M
- FCF Yield
- -19.7%
- Owner FCF Yield
- -21.0%
Balance Sheet
- Cash & Equivalents
- $334.5M
Returns & Capital
- SBC, 3Y Avg
- $9.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$196.0M | — |
| FY2024 | — | -$117.1M | — |
| FY2023 | — | -$43.1M | — |
| FY2022 | — | -$55.9M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges